56,640 Shares in Kura Oncology, Inc. $KURA Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio bought a new stake in Kura Oncology, Inc. (NASDAQ:KURA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 56,640 shares of the company’s stock, valued at approximately $621,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Kura Oncology during the 2nd quarter worth about $115,286,000. Suvretta Capital Management LLC raised its holdings in Kura Oncology by 5.7% during the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after acquiring an additional 459,422 shares in the last quarter. Vanguard Group Inc. boosted its position in Kura Oncology by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after purchasing an additional 39,105 shares during the last quarter. Armistice Capital LLC grew its stake in Kura Oncology by 5.7% in the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after purchasing an additional 264,000 shares in the last quarter. Finally, State Street Corp increased its position in shares of Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares during the last quarter.

Analyst Ratings Changes

Several research firms have recently commented on KURA. Morgan Stanley set a $24.00 price objective on Kura Oncology in a report on Monday, August 24th. Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Jefferies Financial Group set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Kura Oncology Stock Performance

KURA opened at $12.09 on Thursday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology, Inc. has a 12-month low of $7.36 and a 12-month high of $13.90. The business has a 50 day moving average of $11.21 and a 200-day moving average of $9.91. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.59 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. On average, equities research analysts expect that Kura Oncology, Inc. will post -3.25 earnings per share for the current year.

Insider Activity at Kura Oncology

In other news, insider Brian T. Powl sold 4,345 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the sale, the insider owned 169,269 shares in the company, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the sale, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is owned by company insiders.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Diabetes program spun out with $50 million in funding: Kura launched Caspian Therapeutics as a separately financed company to develop KO-7246, a menin inhibitor intended to stimulate pancreatic beta-cell expansion and endogenous insulin production in Type 1 and Type 2 diabetes. The financing was led by BVF Partners and included Eli Lilly, the T1D Fund, Invus, Montanova, Kura, and biotech executives. Kura Oncology launches Caspian Therapeutics with $50 million financing
• Positive Sentiment: Kura retains substantial upside exposure: The oncology company will retain approximately half of Caspian on a fully diluted basis while the subsidiary funds development independently, allowing Kura to participate in potential value creation without bearing all development costs. Preclinical data will be presented at the European Association for the Study of Diabetes meeting on September 29, 2026. Kura creates Lilly-backed spinout
• Neutral Sentiment: New CFO appointed: Jennifer Fulk became Kura’s chief financial officer on September 8. Her background includes biopharmaceutical finance, capital allocation, research and development portfolio management, commercial operations, and investor relations. Kura Oncology appoints Jennifer Fulk as chief financial officer
• Negative Sentiment: Execution risk remains: Caspian’s opportunity is based on preclinical findings, and KO-7246 still needs to demonstrate safety and efficacy in human trials. Investors may therefore remain cautious until the program produces clinical proof of concept.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.